Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
11.65 x 2 33.00 x 3
Pre-market by (Cboe BZX)
29.11 +2.26 (+8.42%) 04/11/25 [NASDAQ]
11.65 x 2 33.00 x 3
Pre-market 29.11 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
26.41
Day High
29.26
Open 26.78
Previous Close 26.85 26.85
Volume 1,379,200 1,379,200
Avg Vol 1,246,205 1,246,205
Stochastic %K 30.55% 30.55%
Weighted Alpha -42.11 -42.11
5-Day Change +2.22 (+8.26%) +2.22 (+8.26%)
52-Week Range 24.10 - 62.53 24.10 - 62.53
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,708,657
  • Shares Outstanding, K 93,049
  • Annual Sales, $ 1,040 K
  • Annual Income, $ -298,410 K
  • EBIT $ -307 M
  • EBITDA $ -319 M
  • 60-Month Beta 0.37
  • Price/Sales 2,404.59
  • Price/Cash Flow N/A
  • Price/Book 1.88

Options Overview Details

View History
  • Implied Volatility 68.88% ( -2.85%)
  • Historical Volatility 61.40%
  • IV Percentile 95%
  • IV Rank 77.47%
  • IV High 79.02% on 04/08/25
  • IV Low 34.00% on 09/24/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 129
  • Volume Avg (30-Day) 231
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 2,333
  • Open Int (30-Day) 3,430

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.99
  • Number of Estimates 8
  • High Estimate -0.80
  • Low Estimate -1.09
  • Prior Year -0.93
  • Growth Rate Est. (year over year) -6.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.10 +20.79%
on 04/09/25
Period Open: 34.26
36.45 -20.14%
on 03/25/25
-5.15 (-15.03%)
since 03/11/25
3-Month
24.10 +20.79%
on 04/09/25
Period Open: 40.59
41.45 -29.77%
on 01/22/25
-11.48 (-28.28%)
since 01/10/25
52-Week
24.10 +20.79%
on 04/09/25
Period Open: 48.03
62.53 -53.45%
on 11/14/24
-18.92 (-39.39%)
since 04/11/24

Most Recent Stories

More News
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

CRNX : 29.11 (+8.42%)
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 29.11 (+8.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly,...

See More

Key Turning Points

3rd Resistance Point 32.96
2nd Resistance Point 31.11
1st Resistance Point 30.11
Last Price 29.11
1st Support Level 27.26
2nd Support Level 25.41
3rd Support Level 24.41

See More

52-Week High 62.53
Fibonacci 61.8% 47.85
Fibonacci 50% 43.31
Fibonacci 38.2% 38.78
Last Price 29.11
52-Week Low 24.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar